Free Fall Webinars – Navigating Partnering Events like a Pro

13 Oct

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

Partnering events can be the best ways to engage with potential investors and strategic partners in the early-stage arena. Life Science Nation is offering a series of free webinars to help life science and healthcare entrepreneurs make the most out of partnering events, such as Digital RESI, November 15-16, 2022 and RESI San Francisco, January 10-12, 2023. These webinars offer tactical advice to early-stage companies on how to maximize outcomes when attending conferences like RESI and moving connections beyond the event. Attend these complimentary webinars and save $1,000 on a special bundle deal for Digital RESI November and RESI San Francisco by October 21.

Register below to join these complimentary online sessions:

October 20, 1:30 PM EDT – Sign-up

The Best Partnering Practice: Virtually vs. Face-to-Face

Greg Mannix, Vice President, International Business Development, General Manager, Europe, Life Science Nation

Partnering in the digital world of the past few years has taught us all new skills. Now that in-person events have returned—often with a “hybrid” component—there are some key tactics you should keep in mind to get the best results.


November 1, 1:00 PM EDT – Sign-up

Partnering Live Tutorial

Antoinette Lowre, Manager, Business Development, Life Science Nation

This partnering tutorial covers basic functions of the RESI partnering platform, how to set up your profile, how to search for investors/strategic partners, how to book and request meetings and what your outreach strategy should look like when requesting meetings.


November 2, 12:00 PM EDT – Sign-up

Pitching at the Biggest Partnering Event of the Year (Session 1)

Karen Deyo, Director, Investor Research, Israel Business Development, Life Science Nation

Alexander Vassallo, Manager, Business Development, Life Science Nation

As RESI returns to JPM week next January, the biggest partnering event of the year for the life sciences industry, so does the Innovator’s Pitch Challenge (IPC). Being able to deliver a powerful and compelling pitch to portray why your company’s unique technology should be an investor’s top interest can help make this week potentially one of the most productive of the year. Join Karen and Alex on this webinar to discuss making the most of your pitch opportunity at JPM week next year!


November 22, 11:00 AM EDT – Sign-up

Pitching at the Biggest Partnering Event of the Year (Session 2)

Candice He, Vice President, Business Development, Global Investment Strategist, Life Science Nation

Claire Jeong, Chief Conference Officer, Vice President, Investor Research, Asia Business Development, Life Science Nation

As RESI returns to JPM week next January, the biggest partnering event of the year for the life sciences industry, so does the Innovator’s Pitch Challenge (IPC). Being able to deliver a powerful and compelling pitch to portray why your company’s unique technology should be an investor’s top interest can help make this week potentially one of the most productive of the year. Join Karen and Alex on this webinar to discuss making the most of your pitch opportunity at JPM week next year!

RESI-November-2022-2-border

RESI-SF-2023-Banner

RESI Sponsorship to Expand Reach and Optimize Impact

13 Oct

By Antoinette Lowre, Manager of Business Development, LSN

Life Science Nation (LSN)’s RESI conference series is one of the only early-stage focused partnering experiences in the life science and healthcare ecosystem. All players use RESI to rally their partnership and fundraising goals. Sponsoring RESI is the fast-track to reaching these goals.

Benefits of sponsoring a RESI conference include increasing global brand and reach, sourcing, vetting and developing key relationships with your target audience, showcase your product and services through workshops and panels, and use our one-of-a-kind match-based partnering platform to connect with strategic partners and build relationships.

New Spnsorship Brochure Cover

Check out our Sponsorship Brochure to meet your goals and reach your intended audience. Contact your BD rep to learn more on how to sponsor and gain visibility at Digital RESI, November 15-16, 2022 and RESI San Francisco, January 10-12, 2023

RESI-November-2022-2-border

RESI-SF-2023-Banner

Back to the Future: In-Person Partnering Conferences are Back with a Vengeance!

13 Oct

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

If the pandemic taught us anything, it is that there is more than one way to skin a cat. Making connections and doing business while being hundreds or thousands of miles apart from our counterparts seemed like a ridiculous proposition only a few years ago, but alas! Nobody thinks that way today.

In fact, the RESI conference successfully created a digital platform for exactly that: making connections and doing business. Early-stage companies, investors, strategics and service providers discovered how to make the best of the situation and be very productive. The usefulness of remote, virtual meetings is evident today and will likely be around for the foreseeable future. But we saw last month at RESI Boston that there is a real desire to return to face-to-face gatherings.

_DSC1104

While virtual meetings will continue to be useful, the return to in-person partnering conferences like RESI Boston and the upcoming RESI San Francisco, January10-12 have important advantages:

  • Ad-hoc meetings throughout the day
  • Networking receptions
  • The undeniable power of a handshake (or elbow bump!)

To that end, any company in the early-stage life sciences arena must have JPM week in January in San Francisco on their radar. It’s the week that thousands of relevant investors, strategic partners and new technology startups converge on the City by the Bay to look for opportunities to connect and do business. Apart from scheduling planned meetings throughout the week, every evening is full of networking events to make more connections. It can be the most productive week of the year for many companies!

RESI San Francisco,, January 10-12, 2023 is a key part of JPM week. For early-stage players, it is, without a doubt, the best venue to identify and meet 500+ global investors and strategic partners. The RESI Partnering Platform allows you to schedule multiple meetings with the right counterparts on January 10. For the following two days, you can schedule both virtual and in-person meetings anywhere in the city using the RESI Partnering Platform.

As a lead-up to JPM week, LSN is offering a Digital RESI, November 15-16 partnering event. You can meet virtually with 200+ investors and strategics to get the most out of the final quarter of 2022 and be ready for new and follow-up meetings in January. We are offering a super discount bundle package for RESI November & RESI JPM San Francisco.

Bundle Package Earlybird Offer – Digital RESI November + RESI JPM San Francisco

RESI-November-2022-2-border

RESI-SF-2023-Banner

Hot Investor Mandate: New Venture Capital Fund Seeks Early-Stage Therapeutics, Medical Device, and Diagnostics Investment Opportunities in USA and Canada

13 Oct

A venture capital fund in the process of raising USD 150 million will be used to invest in around ten to twelve early-stage startups. The fund will primarily look to participate in Series A fundraising but is open to earlier rounds as well. The firm will only participate in equity investments with an initial check size between USD 3 million and USD 7 million. The fund will primarily invest in companies that are based in the United States but is open to considering opportunities in Canada as well.

The firm is interested in investing in companies within the therapeutics, diagnostics, and medical technology sectors. The fund is modality agnostic and open to all companies within these sectors but will not consider investments in digital health. The firm will primarily seek to invest in therapeutics in the pre-clinical and Phase I stages of development as well as devices and diagnostics that are in development and clinical. The fund will invest in all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will consider companies across all indications including orphan diseases.

The firm prefers to work with experienced management teams that are made up of passionate and driven people developing great science. The fund is an active investor that will require a board seat and may act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Arm of Generics Company Invests Globally in Digital Health Companies in the Fields of Chronic Disease, Mental Health, and More

13 Oct

A corporate venture capital arm of a global generic manufacturer headquartered in Western Europe can invest up to $5m in a round. They will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Firm Invests in Tech-Enabled Medtech and Digital Health Companies, With Preference to Those in Clinical Stage

13 Oct

A USA-based venture capital firm had its beginnings as an incubator, providing seed funding to very early-stage companies for the first two years. Since then, the firm has also branched into a venture arm that expanded the investment focus to Series A financing rounds. The firm is actively seeking investments and will allocate around $500K – 2.5 M, with preferred financing structures being equity and convertible preferred equity. Although the firm has invested in companies outside the USA, the firm focuses its investments on USA-based companies.

In the life sciences space, the firm is primarily interested in healthcare IT/digital health technologies and services as well as medical devices and diagnostic tools that have a tech-enabled component. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. Products that have not begun clinical trials will most likely be considered too early, so these devices should at least be undergoing clinical trials. The firm is not interested in companies in the therapeutics sector.

The firm seeks to work with privately owned companies with an experienced management team that is dedicated full-time. CEOs with experience founding successful start-up companies is a strong plus. The firm can act as either a lead or co-investor in financing rounds, and will generally seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Fund Invests in the Earliest Stage Companies, Focusing on Pre-Seed Opportunities in Platform Technologies Including Therapeutics, Digital Health, and More

13 Oct

A thesis-driven earliest stage firm looks to lead investments in early-stage companies that are pre-seed. The firm is currently investing out of their second fund of USD 67 million. The firm primarily participates in equity investments including SAFEs but will consider other types of capital structures as requested by a founder. The firm invests largely in companies based in the United States and Canada but will also consider Europe and Latin America.

The firm is primarily interested in investing in companies in the digital health, diagnostics, and medical technology sectors with a focus in platform technologies. The firm will not consider investments in medical device companies. However, the firm will consider therapeutics with a platform technology component. The firm will only invest in technologies that are still pre-clinical and in development. The firm is disease agnostic and will consider companies across all indications including orphan diseases.

The firm will work with experienced and inexperienced management teams. The firm looks to invest in founders who are dedicated to their technology and their company. The firm is an active investor and will take an observer board seat as determined on a case-by-case basis. The firm prefers to act as a lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.